Aleksey Novikov

Clinical Assistant Professor

University of Florida
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Aleksey Novikov is a Clinical Assistant Professor at the University of Florida, specializing in advanced endoscopic procedures and interventions. His research interests include the comparative efficacy of various endoscopic techniques, the management of pancreatic collections, and the analysis of surgical outcomes. Recent articles authored by Dr. Novikov explore topics such as the efficacy of different approaches to treating gastrointestinal neoplasia and the risk factors associated with endoscopic procedures. He is dedicated to improving patient outcomes through innovative research in the field of gastroenterology.

Articles (13)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Background and Aims Obesity is a risk factor for relapsing inflammatory bowel disease. GLP-1 and dual GLP-1/GIP agonists may offer superior weight loss; however, their effect on inflammatory bowel disease remains unknown. In this study, we assessed outcomes in patients with IBD and obesity using these medications. Methods A retrospective, propensity-matched analysis was conducted using data from The OneFlorida+ network. We evaluated patients with IBD and obesity prescribed GLP-1-based therapy (liraglutide, semaglutide, or tirzepatide) versus those without. 562 patients prescribed GLP-1-based therapies were matched 1:1 to controls based on demographics and comorbidities. Results No differences in GLP-1 users versus non-users with respect to all-cause hospitalization, IBD-hospitalization, IBD-related surgery, or pancreatitis were seen. Use of semaglutide reduced the risk of IBD-related surgery (HR 0.33, CI 0.13-0.83). Among 89 tirzepatide users, none required IBD-related surgery versus 2 matched controls. Black GLP-1 users had an increased risk of all-cause hospitalizations (HR 1.59, CI 1.11–2.29) but not IBD-related hospitalization or IBD-related surgery. Steroid use was comparable between groups. GLP-1 use significantly reduced serum CRP. Conclusions Semaglutide appeared to lower the risk of IBD-related surgery. Black patients using GLP-1 therapy had an increased risk of all-cause hospitalization. Tirzepatide showed no significant difference regarding primary endpoints; however, the sample size was small. Overall, all GLP-1-based therapies were well tolerated among obese patients with IBD. Larger studies are warranted to understand the therapeutic potential of GLP-1-based treatment in this patient population. Graphical Abstract

Year:

2025

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Monica Gaidhane

Associate Professor of Research

-

UNITED STATES
View details

Hao Dai

University of Florida Health

UNITED STATES
View details

ilyas sahin

Massachusetts General Hospital

UNITED STATES
View details

Jingchuan Guo

-

UNITED STATES
View details

Thomas J George

University of Florida

UNITED STATES
View details

Kunzah Syed

Clinical Assistant Professor at the Heritage College of Osteopathic Medicine

Ohio University

UNITED STATES
View details

Jiang Bian

Professor and Vice Chair of Translational Informatics

Indiana University School of Medicine

UNITED STATES
View details